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Abstract The National Institute for Health and Clinical
Excellence (NICE) invited the manufacturer of rituximab
(RTX) [Roche] to submit evidence for the clinical and cost
effectiveness of RTX as first-line maintenance treatment for
patients with follicular non-Hodgkin’s lymphoma (fNHL)
whose disease has responded to induction therapy with RTX
plus cytotoxic chemotherapy (R-CTX) in accordance with the
Institute’s Single Technology Appraisal (STA) process. The
Liverpool Reviews and Implementation Group (LRiG) at the
University of Liverpool was commissioned to act as the Evi-
dence Review Group (ERG). This article summarizes the
ERG’s review of the evidence submitted by the manufacturer
and provides a summary of the Appraisal Committee’s (AC)
decision. The clinical evidence was derived from a multi-cen-
tred, open-label, randomized phase III study (PRIMA) com-
paring first-line maintenance treatment with RTX with
observation only in 1,018 patients with previously untreated
advanced fNHL. Median time to event (MTE) for the primary
endpoint of progression-free survival (PFS) in the RTX arm was
not estimable due to data immaturity; median PFS in the
observation arm was 48.36 months. A statistically significant
benefit of RTX maintenance therapy for PFS was reported
(hazard ratio [HR] 0.55, 95 % CI 0.44–0.68; p\0.0001).
Statistically significant differences in favour of RTX were also
reported for a range of secondary endpoints. Assessment of
overall survival benefit could be not made due to insufficient
events. The ERG’s main concern with the clinical-effectiveness
data presented was their lack of maturity. The submitted
incremental cost-effectiveness ratio was within the NICE
threshold. The ERG questioned the model on a number of
grounds, particularly the use of Markov methodology rather
than patient simulations, the impact of patient age on the out-
come and the projective PFS modelling. The ERG considered it
impossible to draw firm conclusions regarding the clinical or
cost effectiveness of the intervention as the dataset was as yet too
immature. At a third meeting, the AC concluded that RTX could
be recommended as first-line maintenance treatment for patients
with fNHL whose disease has responded to induction R-CTX.
Key Points for Decision Makers
• The clinical and cost effectiveness evidence presented
was based on a well-designed randomized controlled
trial (RCT). The clinical data for the effectiveness of
rituximab as a maintenance treatment appeared to be
promising. However, trials with immature outcome data
pose problems in the assessment of longer-term clinical
and cost effectiveness; this is particularly the case for
diseases that are of prolonged duration. These issues
were clearly apparent during this appraisal
• Data from trials that are stopped early based on a
beneficial treatment effect (typically indicated by a
statistically significant hazard ratio) should be viewed
with caution as the efficacy may be overestimated
• In diseases that are of prolonged duration, it may be more
useful to model outcomes using simulation based on
patient-level data rather than employing a Markov approach
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The National Institute for Health and Clinical Excellence
(NICE) is an independent organization responsible for
providing national guidance to the NHS in England and
Wales on a range of clinical and public health issues, as
well as appraisal of new health technologies. The NICE
Single Technology Appraisal (STA) process [1] is specif-
ically designed for the appraisal of a single health tech-
nology for a single indication, where most of the relevant
evidence lies with one manufacturer or sponsor. Typically,
the process is used for new pharmaceutical products close
to launch. The evidence for an STA is principally derived
from a submission by the manufacturer/sponsor of the
technology, which should be based on a specification
developed by NICE. The manufacturer’s submission (MS)
is critiqued by members of the independent Evidence
Review Group (ERG) who produce a report to be consid-
ered by the NICE Appraisal Committee (AC).
The NICE AC considers the submissions from the
manufacturer and the ERG alongside testimony from
experts, patients and other stakeholders to formulate pre-
liminary guidance. All stakeholders have an opportunity to
comment on this preliminary guidance and the manufac-
turer has the opportunity to provide a supplementary evi-
dence submission. The AC meets again to produce the final
guidance (final appraisal determination [FAD]). This arti-
cle presents a summary of the ERG report for the STA of
rituximab (RTX) as first-line maintenance treatment for
patients with follicular non-Hodgkin’s lymphoma (fNHL)
whose disease has responded to induction therapy with
RTX plus cytotoxic chemotherapy (R-CTX). This is one in
a series of STA summaries being published in Pharmaco-
Economics [2–22].
Full details of all the relevant appraisal documents
(including the appraisal scope, ERG report, manufacturer
and consultee submissions, Appraisal Consultation Docu-
ment [ACD], FAD and comments on each of these) can be
found on the NICE website [23].
2 The Decision Problem
fNHL is one of a group of diseases known collectively as
non-Hodgkin’s lymphomas (NHLs), cancers arising from
the lymphoid cells of the immune system. These cells
normally have a key role in protecting the body from
pathogenic microorganisms. Malignant transformation of
lymphocytes results in their uncontrolled replication usu-
ally starting within the lymph nodes, mainly those of the
neck, armpits and groin. Swelling of these structures often
provides the first clinical manifestation of illness, although
other symptoms including fever, drenching night sweats,
weight loss (‘B-symptoms’) and tiredness may also be
present at diagnosis or develop later. The incidence of
NHL is similar in men and women and increases with age:
rates increase sharply in people over 50 and around two-
thirds of all cases are diagnosed in people over 60 years of
age [24].
The estimated number of new cases of NHL in the USA
for 2011 is 66,000 [25]. Australian projections for new
cases of NHL for 2010 are 4,000 [26]. For Europe as a
whole, the estimated number of new cases for 2008 was
52,000 [27]. In England and Wales in 2008, there were
almost 12,000 new cases of NHL recorded [24]. Between
22 % and 40 % of NHLs are fNHL [28, 29]. The majority
of cases of fNHL are diagnosed at an advanced stage (III/
IV) [30].
Typical estimates of median survival for patients with
advanced fNHL are 8–10 years from diagnosis [31, 32].
However, recent evidence [33–36] suggests that survival
may be longer, probably as a consequence of improved
treatment. The natural course of advanced disease is of a
series of treatment-induced remission followed by relapse,
with each remission duration becoming shorter and fewer
patients responding to each cycle of therapy [37, 38].
Patients in the UK diagnosed with advanced fNHL and
who are symptomatic, have a high tumour burden, rapid
disease progression or other key features are normally
offered induction treatment with R-CTX [29].
The aim of using RTX maintenance therapy (375 mg/m2
body surface area, by intravenous infusion once every
2 months until disease progression, or for a maximum of
2 years) following response to induction therapy is to
extend and deepen the first remission [37, 38]. It would be
expected, as in the relapsed/refractory setting, that exten-
ded progression-free survival (PFS) as a consequence of
RTX maintenance therapy will delay the time to first
relapse and, therefore, the burden of further CTX treatment
[39, 40].
NICE developed a scope for the assessment of RTX,
which specified that the clinical and cost effectiveness of
this drug should be established within its licensed indica-
tion relative to standard management without RTX main-
tenance therapy (observation) and ibritumomab tiuxetan
(Zevalin). Five outcome measures were considered rele-
vant to the appraisal: PFS, overall survival (OS), response
rates, adverse effects (AEs) of treatment and health-related
quality of life (HR-QOL). The time horizon of analysis was
stipulated as sufficiently long to reflect any differences in
costs or outcomes between the technologies being
compared.
At the time of this appraisal, the licence for RTX as a
maintenance therapy was limited to use in patients with
relapsed/refractory lymphoma. However, the European
Medicines Agency’s (EMA) Committee on Medicinal
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Products for Human Use had issued a positive opinion to
extend the use of first-line RTX maintenance therapy to
include the treatment of fNHL patients responding to
induction therapy. The licence extension was granted by
the EMA in December 2010 [41].
3 Independent ERG Report
The ERG examined and critiqued the initial MS and two
subsequent supplementary evidence submissions from the
manufacturer as well as taking into consideration the
manufacturer’s response to the ERG’s request for clarifi-
cation on a number of issues. The ERG report comprised a
critical review of the evidence for the clinical and cost
effectiveness of the technology and embodied three aims:
• To assess whether the MS conformed to the method-
ological guidelines issued by NICE
• To assess whether the manufacturer’s interpretation and
analysis of the evidence were appropriate
• To indicate the presence of other sources of evidence or
alternative interpretations of the evidence that could
help inform NICE guidance
In addition to providing this detailed critique, the ERG
modified a number of key assumptions and parameters
within the manufacturer’s economic model to examine the
impact of such changes. The next section summarizes the
evidence submitted by the manufacturer and the ERG’s
review of that evidence.
3.1 Clinical Evidence
The clinical-effectiveness evidence was derived from a
single trial, PRIMA (Primary Rituximab and Maintenance
trial) [42], which was unpublished at the time the MS was
submitted to NICE. The PRIMA trial results are now
published [43]. The MS was based on data from the clinical
study report. The PRIMA trial [42] was an international,
multi-centred, open-label, randomized phase III study
(n = 1018) designed to evaluate the efficacy of RTX
maintenance treatment compared with observation for
patients with advanced fNHL whose disease had responded
to induction treatment with R-CTX.
The outcomes of the trial are described in Table 1. For
the primary endpoint of PFS (defined as first documented
disease progression, relapse or death from any cause), at
median follow-up of 38 months, the median time to event
(MTE) for patients in the RTX arm was not estimable due
to insufficient PFS events; the median PFS in the obser-
vation arm was 48.36 months. A statistically significant
benefit of RTX maintenance therapy for PFS was reported
(hazard ratio [HR] 0.55, 95 % CI 0.44–0.68; p \ 0.0001).
For secondary endpoints at a median follow-up of
36 months, statistically significant differences were repor-
ted for event-free survival (HR 0.59, 95 % CI 0.48–0.72;
p \ 0.0001), time to next anti-lymphoma treatment (HR
0.60, 95 % CI 0.47–0.76; p \ 0.0001), time to next CTX
treatment (HR 0.62, 95 % CI 0.47–0.81; p = 0.0005) and
overall response rate (difference in proportions 17.98,
95 % CI 12.3–23.6; p \ 0.0001), although the only cal-
culable MTE was for event-free survival (first documented
progression, relapse, initiation of new anti-lymphoma
treatment or death from any cause) in the observation arm.
No meaningful conclusions regarding OS could be drawn
due to the lack of deaths. The incidence of AEs was higher
in the RTX arm than the observation arm; however, no
unexpected safety findings were reported. No statistically
significant differences were reported on the outcome of
QOL as measured by the Functional Assessment of Cancer
Therapy—General (FACT-G) questionnaire [44] and the
European Organization for Research and Treatment of
Cancer Quality of Life Questionnaire (EORTC-QLQ C30)
[45].
The manufacturer dismissed Zevalin as a comparator on
the grounds that (1) there is no clinical evidence to support
the clinical benefit of Zevalin in patients with untreated
advanced fNHL, and (2) there is minimal Zevalin use in
UK clinical practice.
3.1.1 Critique of the Clinical Evidence and Interpretation
The ERG considered the PRIMA trial [42] to be large and
well designed, with safeguards to mitigate against possible
bias in monitoring and assessment (particularly important
since the trial was open label). The ERG’s opinion was that
the results of the trial were generalizable to UK clinical
practice as the participants in the trial were comparable
with patients seen in UK clinical practice and the majority
were recruited from countries with similar care pathways to
the UK. The ERG considered that the manufacturer had
made a convincing case for not including Zevalin as a
comparator.
The ERG’s chief concern was the immaturity of the
outcome data. This immaturity stemmed from two factors:
the early closure of the trial (recommended by the study
Data and Safety Monitoring Committee on the grounds of
benefit [i.e. that the primary endpoint of PFS was crossed
in favour of the maintenance arm]) and the limited follow-
up data available for report in the MS. At the time of study
closure, 1,018 patients were enrolled, 505 and 513 in the
RTX and observation arms, respectively. Of these patients,
only 93 (18.4 %) in the RTX arm and 174 (33.9 %) in the
observation arm had progressed at the time of analysis.
None of the patients had been followed up for more than
4 years.
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The ERG’s concerns regarding the immaturity of the
data were supported by the findings of a meta-analysis [46],
which reported large differences in treatment effect sizes
between trials that were stopped early and similar trials that
ran their full course. This finding, based on a comparison of
91 trials (cancer and non-cancer trials) that were terminated
early based on a beneficial treatment effect (typically
indicated by a statistically significant hazard ratio) with
424 similar trials that ran to full term, was robust regardless
of the methodological quality of the trials or the presence
of statistical stopping rules [46].
3.1.2 ERG Conclusions on the Submitted
Clinical Evidence
Whilst the clinical trial data appeared to show a benefit for
patients in the RTX arm, the ERG considered that the data
submitted were too immature to draw definite conclusions.
Longer follow-up with more events would be required
before informed decisions could be made regarding the
clinical effectiveness of RTX as a first-line maintenance
therapy compared with observation.
3.2 Cost-Effectiveness Evidence
The MS included a review of the literature of the cost
effectiveness of RTX as a first-line maintenance treatment
in fNHL; no relevant published economic evaluations were
identified.
The manufacturer undertook a de novo economic eval-
uation of RTX first-line maintenance therapy (intervention)
compared with observation (comparator) for the treatment
of patients with fNHL responding to first-line induction.
The economic model was developed over a 25-year time
horizon to capture the lifetime costs and QALYs of an
average patient with fNHL and took an NHS and Personal
Social Services perspective.
The economic model developed by the manufacturer
was a four-state Markov model with a cycle length of
1 month. Patients enter the model in the PFS1 state (dis-
ease-free) having successfully completed induction therapy
with R-CTX. Patients who responded to R-CTX either
receive RTX monotherapy maintenance therapy (for
2 years) in the intervention arm or do not receive any
treatment in the comparator arm. After initial treatment, at
Table 1 Key outcomes of the PRIMA trial
Endpoint RTX (N = 505) Observation (N = 513) HR (95 % CI) P value
Primary: investigator-assessed PFS (38 months)
Median time to event (95 % CI) NE 48.36 (42.09 to NS) 0.55 (0.44–0.68) \0.0001
Secondary endpoints (36 months)
Event-free survival
Median time to event NE 1381 days [45.4 months]
25th percentile 1000 days [32.8 months] 497 days [16.3 months] 0.59 (0.48–0.72) \0.0001
1-year event-free rate (95 % CI) 0.89 (0.86–0.92) 0.81 (0.78–0.84)
Overall survival
Median time to event NE NE
25th percentile NE NE 0.87 (0.45–1.47) 0.6010
1-year event-free rate (95 % CI) 0.99 (0.98–1.00) 0.99 (0.98–1.00)
Time to next anti-lymphoma treatment
Median time to event NE NE
25th percentile 1328 days [43.6 months] 775 days [25.5 months] 0.60 (0.47–0.76) \0.0001
1-year event-free rate (95 % CI) 0.92 (0.89–0.94) 0.89 (0.87–0.92)
Time to next CTX treatment
Median time to event NE NE
25th percentile NEa 975 days [32.0 months] 0.62 (0.47–0.81) 0.0005
1-year event-free rate (95 % CI) 0.92 (0.90–0.95) 0.91 (0.89–0.94)
The table is adapted from the manufacturer’s submission and is reproduced from Greenhalgh et al. [54] (Crown copyright)
P values and HRs were calculated using the stratified log-rank test and stratified Cox regression for time-to-event endpoints, respectively.
Stratification factors were induction treatment received and response to induction treatment. P values for response rate were calculated using the
v2 test
CI confidence interval, CTX cytotoxic chemotherapy, ERG Evidence Review Group, HR hazard ratio, NE not estimable, NS not stated, PFS
progression-free survival, RTX rituximab
a The ERG notes that this NE is likely to be a typing error as a figure was reported at an earlier time point
406 J. Greenhalgh et al.
the end of each cycle patients remain in PFS1 or progress
to PFS2 (remission/full response to second-line RTX
monotherapy in accordance with NICE’s technology
appraisal [TA] 137 [47]) or die. Once in the PFS2 health
state, a patient may remain in this health state, die at the
end of each cycle or move to progressive disease (PD).
Patients in the PD state cannot move back to PFS2; they
can either remain in PD or die at the end of each cycle.
Death is an absorbing health state.
The model was populated with clinical-effectiveness
results from the PRIMA trial [42] at median follow-up of
38 months and from an earlier trial of maintenance treat-
ment with RTX following second-line CTX treatment,
known as EORTC 20981 [39, 40]. HR-QOL utility values
were taken from a paper [48] reporting a study that had
originally been commissioned by Roche, and the main
sources of cost data were the NHS Reference Cost Schedule
2008–2009 [49] and the British National Formulary
(56–59) [50].
The manufacturer’s base-case incremental cost-effec-
tiveness ratio (ICER) for RTX for the first-line mainte-
nance treatment of patients with fNHL compared with
observation was £15,978 per QALY gained and £14,697
per life-year gained. The manufacturer was confident that
probabilistic sensitivity analysis results supported the
robustness of the cost effectiveness of RTX maintenance
therapy compared with observation in patients with fNHL
responding to first-line induction therapy.
3.2.1 Critique of the Cost-Effectiveness Evidence
and Interpretation
The ERG identified that the main source of uncertainty in
the economic model was the immature nature of the pri-
mary data source, i.e. the PRIMA trial [42]. The submitted
model projected future benefits in terms of increased
patient time in PFS, and this was the dominant driver of
cost effectiveness. In the manufacturer’s base-case results,
the model estimated the mean (undiscounted) survival for
patients without maintenance therapy as 11.44 years, and
13.38 years for those with RTX maintenance therapy: a
gain of 1.94 years. The model also estimated the mean time
spent in PFS as 8.64 years (observation only) and
10.65 years (RTX maintenance): a gain of 2.01 years.
Virtually all this benefit was generated in the first PFS
phase of the model, with the implication that PFS gains are
translated almost entirely (96.6 %) into OS gains. The
ERG considered this a ‘best possible’ scenario that
required robust supportive evidence from clinical trials
before it could be accepted. At present [51], there is no
unequivocal evidence from any clinical trial or meta-
analysis that RTX maintenance treatment of patients with
fNHL offers any significant OS gains, despite good
evidence of PFS gains. The PFS advantage from first-line
RTX maintenance therapy directly measurable from the
mature PRIMA trial data [42] (up to 800 days from ran-
domization using the latest clinical data available)
amounted to no more than 60 days.
A number of issues relating to the model design and
structure, and to the implementation of the model were also
raised by the ERG. These included:
• Health states and pathways: Due to the long/lifetime
duration and complex pathways associated with fNHL,
it is very difficult to represent real-life patterns of care
adequately within a Markov framework as Markov
models require the definition of essentially homoge-
neous health states in which patients share common
risks, utility and treatment costs regardless of their prior
history. There is a strong rationale for employing
patient-level simulation methods in preference to a
Markov model in such situations.
• Principal model driver: PFS is the principal driver of
health gain in the model. However, the ERG considered
‘time to next anti-lymphoma treatment’ to be a more
appropriate outcome variable as this provides a better
reflection of clinical reality.
• Use of both PRIMA [42] and EORTC 20981 [39, 40]
trial data to populate the model: The populations in
these two trials are at different stages of their disease
career and therefore the appropriateness of using data
from the two trials is questionable.
The main implementation issue identified by the ERG
was the manufacturer’s use of different utility values for
PFS1 (disease-free) and PFS2 (remission/full response to
therapy); there should be no difference in utility as both
groups of patients are in ‘remission/full response’. Other
identified issues included inconsistent logic in estimating
deaths, errors in the calculations of patients eligible for
second-line treatment and inaccurate and inappropriate
estimation of event rates from EORTC 20981 [39, 40].
Errors were also noted regarding discounting, mid-cycle
correction, AE costs, costs of RTX treatment, timing of
RTX doses and health state costs.
3.2.1.1 ERG Sensitivity Analyses The ERG carried out
sensitivity analyses (SAs) around two aspects of the man-
ufacturer’s model that appeared to be influential in gov-
erning the cost-effectiveness results; namely, patient age
and the assumed duration of clinical benefit (Table 2).
The ERG’s clinical advisor confirmed that the age at
which a patient is diagnosed with fNHL and begins their
first course of CTX is of great importance in determining
the potential benefit that may accrue from the use of a
novel regimen. The ERG requested additional results via
the clarification process to allow a comparison of clinical
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effectiveness between three age-based subgroups. Despite
the immaturity of the PRIMA trial data [42] and the
unsophisticated nature of the analysis, there appeared to be
an emerging trend indicating a reduction in clinical effect
as patient age increased—a curvilinear trend in odds ratio
(OR), equivalent to a linear trend in relative risk. The HR
of PFS in the base-case model was adjusted by the ERG to
reflect specific patient ages; the results indicated that the
combined effect of increasing mortality and reducing
effectiveness could alter the estimated ICER substantially.
For example, considering patient cohorts with ages at
induction of 30, 60 and 90 years generated ICERs of
£9,790, £18,055 and £43,306, respectively.
As a consequence of the immaturity of the PRIMA trial
data [42] (RTX was not given to patients beyond 2 years),
the manufacturer was obliged to model the long-term effect
of RTX, making an assumption of the average period for
which treatment continued to provide additional clinical
effect. In the base case, the manufacturer considered a
period of 6 years, but without reference to any supporting
evidence. Three alternatives were put forward by the ERG:
26 months (the period over which data were available, i.e.
800 days), 4 years (equivalent to the maximum time over
which any patients had been observed within the PRIMA
trial [42]), and 40 years (equivalent to a lifetime). These
time periods generated ICERs per QALY gained of
£32,230, £21,151 and £8,966, respectively.
However, when considering these results it is important
to note a major assumption used in the manufacturer’s
model, namely that, at the end of the assumed ‘effective
period’, the hazard governing the PFS projective model
reverts to the hazard of the comparator arm, but from a
higher absolute survival level. This approach means that
the survival curves of the intervention and comparator arms
will never converge within a finite time, ensuring that the
RTX arm continues to accumulate survival gains long after
the supposed limit of clinical effectiveness. This assump-
tion precludes an alternative process observed in some
clinical trials, whereby clinical gains begin to decay at the
end of active treatment, until the intervention and com-
parator survival curves converge to the same long-term
trajectory after a few months or years. In simple terms, the
difference can be characterized as follows:
• The manufacturer’s approach assumes that the clock
governing the disease process is ‘turned back’ for
patients on RTX maintenance therapy by several years,
so that it never catches up with that experienced by
untreated patients.
• The alternative process assumes that the disease clock is
slowed down by RTX for several years, but accelerates
when the effect wears off, and eventually catches up
with the disease experienced by the untreated patients.
The difference in health gain between these two mod-
elling approaches was difficult to estimate using the man-
ufacturer’s model. However, in the manufacturer’s base
case, more than 72 % of the estimated PFS gain arises after
the 4-year point; there is, therefore, considerable scope for
a reduction in incremental outcomes if the initial PFS
advantage is lost progressively. The estimated ICER could
increase by as much as three times, depending on the time
over which the gap between PFS curves disappears.
3.2.2 ERG Conclusions on the Submitted
Cost-Effectiveness Evidence
Overall, the ERG considered that direct use of the model
results was too heavily affected by extensive and often
unquantifiable uncertainty around the central claims of
clinical benefit to be useful for decision making, i.e. the
clinical data available made it impossible to compare the
cost effectiveness of first-line RTX maintenance therapy
with observation in patients with fNHL with any confi-
dence. In addition, several important model assumptions
(the age of patients, the assumed duration of benefit from
maintenance RTX therapy) indicated much greater uncer-
tainty in the manufacturer’s model cost-effectiveness
results than was suggested in the MS.
3.3 Conclusions of the ERG Report
The ERG concluded that the results of the PRIMA trial
[42] appeared promising; however, the early closure of the
trial combined with limited follow-up resulted in an
immature dataset. Too few patients had experienced events
to draw any firm conclusions on clinical and cost effec-
tiveness from the data available.
4 Key Methodological Issues
Clearly in this case, the data from the key clinical trial were
immature and there was a lack of unequivocal data avail-
able to the manufacturer to support claims of PFS or OS
benefit. Data from a longer follow-up would obviate the
need for assumptions to be made around key variables. The
ERG also considered that in the case of diseases such as
fNHL that are of lengthy duration with complex treatment
pathways, patient-level simulations rather than the Markov
approach would better represent patient experience.
5 NICE Guidance
In June 2011, following three meetings, the AC recom-
mended first-line RTX maintenance therapy as an option
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for the treatment of people with fNHL whose disease has
responded to first-line induction therapy with R-CTX.
5.1 Consideration of Clinical- and Cost-Effectiveness
Issues
5.1.1 First AC meeting
5.1.1.1 Immature Trial Data The ERG’s concerns
regarding the immature results of the PRIMA trial [42] were
discussed. The AC noted that the time to progression could
not be estimated for patients in the RTX arm as too few
patients had experienced disease progression at the time of
data analysis. In addition, any OS benefit could not be cal-
culated because of the small number of deaths. The AC also
noted the early closure of the trial and considered evidence
presented by the ERG that suggested that trials stopped
earlier than planned often overestimate clinical benefit.
However, following advice from clinical experts, the AC
was satisfied that the PFS reported for patients in the RTX
arm of the PRIMA trial [42] reflected observations from
clinical practice. The AC concluded that the available evi-
dence showed that first-line maintenance treatment with
RTX significantly improves PFS compared with observation
but that the size of any OS benefit could not be determined.
5.1.1.2 Appropriateness of the Economic Model The AC
agreed that the manufacturer’s model was acceptable to
address the decision problem.
5.1.1.3 Duration of Clinical Benefit of Treatment The
manufacturer’s base-case assumption of 6 years of clinical
benefit following RTX maintenance treatment was exam-
ined. Clinical experts informed the AC that the actual
benefit is more likely to be around 3–4 years. The AC also
acknowledged that when the ERG estimated the clinical
benefit to last 3–4 years, the size of the ICER increased.
5.1.1.4 Conversion of PFS to OS The AC discussed the
manufacturer’s assumption of a 96.6 % conversion of PFS to
OS and heard from the clinical specialists that the specific
conversion factor cannot be verified from the literature or
clinical experience. The clinical specialists considered a
conversion closer to 70 % to be the most plausible. The AC
acknowledged that the assumption of a conversion factor of
70 % would increase the base-case ICER. The AC was of the
opinion that data from patient registries should have been used
to validate the conversion factor assumed for the base-case
estimate, and to confirm the degree to which RTX mainte-
nance treatment might prolong life. The AC concluded that the
manufacturer’s base case underestimated the true ICER.
5.1.1.5 Patient Age The AC noted the mean age
(56 years) of the patients in the PRIMA trial [42]. The
clinical specialists stated that the mean age of patients at
the start of treatment in the UK is between 60 and 65 years.
The AC acknowledged that people in clinical trials tend to
be younger and fitter than those in clinical practice and
noted from the ERG’s suggested modification that the
manufacturer’s base-case ICER increased when the mean
age at first treatment was assumed to be 60 and 65 years,
respectively.
5.1.1.6 Utility Values The manufacturer’s model inclu-
ded utility values of 0.88 and 0.79 for PFS1 and PFS2
health states, respectively. The AC noted that the ERG
considered there should be no difference in the utility
values used in the model to describe PFS1 and PFS2 as
both groups of patients are in ‘remission/full response’.
When corrected by the ERG, the revision reduced the
QALY gain in PRIMA [42] PFS by more than 10 % and
therefore increased the ICER by approximately 11 %.
The AC agreed that the ICERs presented by the manu-
facturer were largely driven by gains in OS and considered
that the model underestimated the utility associated with
delaying CTX treatment and that if it was included, it
would likely decrease the size of the ICER.
5.1.2 Summary and Outcome of the First AC Meeting
The AC agreed that the key drivers of cost effectiveness
were (1) the assumptions concerning the duration of clin-
ical benefit of maintenance RTX therapy, (2) the conver-
sion of PFS to OS and (3) the underestimation in the
economic model of the utility associated with delaying
CTX treatment following the first relapse.
The AC concluded that it was difficult to establish the
most plausible ICER for RTX maintenance treatment
because SAs to capture preferred assumptions were not
available; however, the ICER may be within the range
that is consistent with an appropriate use of NHS
resources.
The first ACD [52] recommended the use of first-line
maintenance RTX treatment for patients with fNHL who
have responded to induction R-CTX therapy provided that
the manufacturer addressed the uncertainties within a
revised cost-effectiveness analysis:
• for people who are aged 60 to 65 years at the start of
treatment, and
• in which the duration of clinical benefit from [RTX]
maintenance treatment is 3 to 4 years, and
• in which the extent that [PFS] translates into [OS] is
informed by the best available evidence, which could
include patient registries and prospective observational
data. Analyses should be presented for a range of
plausible values, from 50 % to 100 %, and
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• in which utility gains associated with delaying the need
for [CTX] after relapse are included [52].
5.1.3 Second AC Meeting
The AC concluded that the ICERs presented in the man-
ufacturer’s revised submission were associated with a great
deal of uncertainty. Further clarification was sought from
the manufacturer as follows:
1. Exploration of the duration of benefit at different
intervals (28 months, 36 months or 48 months)
2. Additional analyses that assume a conversion factor of
70 %, 80 % or 90 %
3. The mean age of patients at the start of treatment to be
62.5 years [52]
At the end of the second meeting, the AC was minded
not to recommend RTX maintenance treatment for this
indication as a cost-effective use of NHS resources.
5.1.4 Third AC Meeting
The AC considered the manufacturer’s SAs that assumed a
duration of treatment effect of 28 months, 36 months and
48 months and noted that the ICERs ranged from £17,300
to £27,400 per QALY gained. It was noted that the esti-
mates were lower than the ERG scenarios; however, the
manufacturer and the ERG had used different modelling
approaches. The AC was satisfied that the manufacturer’s
SAs presented the most plausible range of estimates for the
treatment effect in line with clinical opinion and the
available data. The AC was also satisfied that the manu-
facturer’s SAs, which assumed conversion rates of 70 %,
80 % and 90 %, provided a plausible range of conversion
rate estimates.
In its final deliberations, the AC noted that the manu-
facturer’s ICERS for RTX maintenance therapy compared
with observation were less than £30,000 per QALY gained
for most scenarios and the ERG ICERs ranged from
£24,600 to £35,000 per QALY gained (depending on the
conversion rate of PFS to OS). The AC also noted that the
model did not include the utility associated with delaying
CTX, and that if it were included it would decrease the
ICER to an estimate that would be considered as a cost-
effective use of NHS resources. The AC therefore recom-
mended the use of RTX in this indication.
6 Conclusion
The main problem in this appraisal was the uncertainty of
the clinical and cost effectiveness of RTX as a maintenance
treatment for patients with fNHL whose disease had
responded to induction treatment with R-CTX. The
uncertainty was a direct result of the immature data pre-
sented as evidence of clinical effectiveness. The reported
data appeared promising, but the lack of events mitigated
against drawing any firm conclusions for either clinical or
cost effectiveness. The early closure of the trial was of
further concern given that evidence indicates that trials
stopped early tend to overestimate treatment effects [46].
At the time that the ERG report was written, the median
PFS for the RTX arm of the trial was not estimable;
however, PFS was the key driver of the economic model.
In the view of the ERG, the manufacturer was unable to
predict the duration of the clinical effect of RTX mainte-
nance therapy on PFS with any plausible certainty. Addi-
tionally, the manufacturer was unable to justify any
assumptions regarding a direct survival benefit from
increased PFS as the PFS to OS gain ratio in this disease
area is unknown.
The ERG maintained the position throughout the pro-
cess that the trial data were too immature to derive any firm
conclusions regarding the clinical and cost effectiveness of
RTX as a maintenance treatment and considered that any
re-manipulation of the limited data available would not
address any of the existing uncertainties. Only a fully
mature dataset would adequately address these. As noted
by the EMA [53] in its evaluation of the data from the
PRIMA trial [42], a median follow-up of about 2 years is
relatively short for the assessment of the long-term benefit
of RTX maintenance treatment. The ERG awaits the pub-
lication of more mature data from the PRIMA trial [42].
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